We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 1

Figure 1. Progression-free Survival and Subgroup Analyses. From: Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations.

Panel A shows Kaplan–Meier curves for progression-free survival, with progression assessed by the site investigators, in an analysis comparing two doses of combination therapy — 150 mg of dabrafenib twice daily plus once-daily trametinib at a dose of either 1 mg (combination 150/1) or 2 mg (combination 150/2) — with dabrafenib monotherapy (mono). Panel B shows subgroup analyses for patients receiving either combination 150/2 or monotherapy. Both these analyses were performed in part C of the study. The melanoma staging criteria of the American Joint Committee on Cancer are defined as follows: stage IIIc, metastases to 4 or more nodes (or in-transit metastasis); and stage IV, metastases beyond nodes. The criteria for distant metastasis are defined as follows: M0, no detectable evidence of distant metastases; M1a, metastases to skin, subcutaneous tissue, or distant lymph nodes; M1b, metastases to lung; and M1c, metastases to all other visceral sites or distant metastases to any site combined with an elevated serum lactate dehydrogenase (LDH) level. ULN denotes upper limit of the normal range.

Keith T. Flaherty, et al. N Engl J Med. ;367(18):1694-1703.

Supplemental Content

Filter your results:

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk